oncnursingnews1d
Enhancing Early-Stage NSCLC Care: Streamlining Biomarker Testing and Multidisciplinary Coordination Through Quality Improvement Initiatives
Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure ...
oncnursingnews3d
How to Overcome 4 Common Barriers to Cancer Clinical Trial Access
An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and ...
oncnursingnews4d
FDA Delays Decision Date for Zenocutuzumab in Lung, Pancreatic Cancer
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...
oncnursingnews5d
Laura Joszt
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews5d
John Sweetenham, MD, FACP, FRCP
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews5d
ERIC BLACKSTONE, MA
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews5d
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
oncnursingnews6d
Kathryn Ciccolini
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews6d
Julie Huynh, MS
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews6d
Samantha Stephens
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews6d
Kristina Davis
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...